The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive NSCLC in Korea: KCSG LU-19-22.
 
Hyun Ae Jung
No Relationships to Disclose
 
Min Hee Hong
Stock and Other Ownership Interests - GI biome; GI cell
Honoraria - AstraZeneca; AstraZeneca; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Merck; Roche; Yuhan
Research Funding - Yuhan
 
Hyun Woo Lee
No Relationships to Disclose
 
Kyung Hee Lee
No Relationships to Disclose
 
Ilhwan Kim
No Relationships to Disclose
 
Young Joo Min
No Relationships to Disclose
 
Hee Kyung Ahn
No Relationships to Disclose
 
Byoung Yong Shim
No Relationships to Disclose
 
Yoon Hee Choi
No Relationships to Disclose
 
Yun-Gyoo Lee
No Relationships to Disclose
 
Jeong A. Kim
No Relationships to Disclose
 
Joung Soon Jang
No Relationships to Disclose
 
Seong-Hoon Shin
No Relationships to Disclose
 
Keon Uk Park
No Relationships to Disclose
 
Keunchil Park
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; JNJ; Lilly; LOXO; Merck KGaA; MSD; Ono Pharmaceutical; Puma Biotechnology
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca; MSD Oncology
 
Jin Hyoung Kang
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genexine; MSD Oncology; Ono Pharmaceutical; Yuhan
Speakers' Bureau - Boehringer Ingelheim; Pfizer; Roche
Research Funding - AstraZeneca; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical; Yuhan